Journal: Journal of Inflammation Research
Article Title: HMGCS2 Palmitoylation Promotes Diabetes-Induced Erectile Dysfunction Through PPARα-Mediated Macrophage Extracellular Trap Formation
doi: 10.2147/JIR.S623377
Figure Lengend Snippet: Palmitoylation inhibitor CMA attenuates MET formation and macrophage infiltration in corpus cavernosum of DMED model rats. ( A-D ) Detection of levels of cfDNA, MPO, NE, and PAD4 in corpus cavernosum of control rats, DMED model rats, and DMED model rats with CMA administration. ( E ) Representative IHC staining of MPO, NE, and PAD4 in corpus cavernosum of control rats, DMED model rats, and DMED model rats with CMA administration. Scale bars, 50 μm. ( F–H ) Quantification of the protein expression levels of MPO, NE, and PAD4 in corpus cavernosum of control rats, DMED model rats, and DMED model rats with CMA administration. ( I ) Representative flow cytometry of CD68 + , CD11b + , and F4/80 + macrophages in corpus cavernosum of control rats, DMED model rats, and DMED model rats with CMA administration. ( J ) Quantification of the ratios of CD68 + , CD11b + , and F4/80 + macrophages in corpus cavernosum of control rats, DMED model rats, and DMED model rats with CMA administration. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001 derived from one-way ANOVA followed by Tukey’s post hoc test.
Article Snippet: Primary antibodies included: HMGCS2 (ab305,227; Abcam, USA), peptidyl arginine deiminase 4 (PAD4; 17,373-1-AP; Proteintech, China), macrophage elastase (ME; 22,989-1-AP; Proteintech), MPO (22,225-1-AP; Proteintech), GAPDH (T0004; Affinity, USA), β-Tubulin (66,240-1-Ig; Proteintech), and PPARα (66,826-1-Ig; Proteintech).
Techniques: Control, Immunohistochemistry, Expressing, Flow Cytometry, Derivative Assay